Hikma Pharmaceuticals Q1-2026 supplier risk profile: 98 shipments, 11 sources, Germany-heavy.
Hikma Pharmaceuticals (US) recorded 98 shipments across 11 suppliers in Q1 2026, sourcing from 7 countries. Germany dominated the footprint at 48% of shipments, driven primarily by Solupharm Pharmazeutische with 36 shipments. The company also sourced 23 shipments from its Jordan-based affiliate and maintained smaller volumes from suppliers in China, Portugal, Italy, and India. No HS chapter data is available for this period.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
One name matching a sanctions watchlist was detected among Hikma's import activity. No suppliers registered UFLPA forced-labor exposure in the available supply chain data.
11 distinct tier-1 suppliers in Q1 2026
| SOLUPHARM PHARMAZEUTISCHE | Germany | 36 |
| HIKMA PHARMACEUTICALS | Jordan | 23 |
| AEROPHARM | Germany | 10 |
| ZHEJIANG NOVUS PHARMACEUTICALS | China | 8 |
| HIKMA FARMACEUTICA PORTUGAL | Portugal | 7 |
| MEDILIFE | Italy | 2 |
| QILU PHARMACEUTICAL HAINAN | China | 1 |
| SRI KRISHNA PHARMACEUTICALS | India | 1 |
Share of Q1 2026 inbound shipments by source country
17 tier-2 + 76 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.